SCHEDULE: Nantahala Capital Discloses 9.99% Stake in Grace Therapeutics

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Grace Therapeutics, Inc. as of June 30, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack collectively reported beneficial ownership of 1,404,032 shares of Grace Therapeutics, Inc. Common Stock.
• This ownership represents 9.99% of the total outstanding shares of Grace Therapeutics, Inc. as of June 30, 2025.
• The reported shares include 225,831 shares that can be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• The Reporting Persons hold shared voting power and shared dispositive power over all 1,404,032 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects, beyond the neutral fact of an investment firm holding a significant stake.

Positives

• The disclosure of a significant ownership stake by an investment adviser like Nantahala Capital Management can signal confidence in the company's long-term prospects.
• The stake is held for investment purposes in the ordinary course of business, indicating no immediate intent to influence or change control.

Negatives

• The filing itself does not contain negative financial or operational information; it is a disclosure of ownership.

Risks

• The filing does not detail specific risks related to Grace Therapeutics, Inc. beyond the inherent market risks associated with holding common stock.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Grace Therapeutics, Inc.'s future outlook.

Industry Context

This Schedule 13G filing indicates a significant investment by Nantahala Capital Management in Grace Therapeutics, Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such disclosures are common in the investment landscape, reflecting institutional interest in specific companies within their respective industries.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing market perception and liquidity.
• Investment Professionals: Offers insight into the investment strategies of Nantahala Capital Management and their conviction in Grace Therapeutics, Inc.

Key Dates

Keywords

Grace Therapeutics, Nantahala Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals